Concurrent drug treatment at the baseline and the end of follow-up
| At the baseline after randomisation | At the end of follow-up | |||
|---|---|---|---|---|
| Diuretics group (n=544) | No-diuretics group (n=586) | Diuretics group (n=504) | No-diuretics group (n=565) | |
| Thiazide diuretics | 518 (98.9) | 0 (0) | 379 (75.2) | 32 (5.7) |
| ACE inhibitors | 53 (10.1) | 86 (14.9) | 42 (8.3) | 70 (12.4) |
| ARB | 292 (55.7) | 388 (67.0) | 349 (69.3) | 377 (66.7) |
| Ca antagonist | 284 (54.2) | 437 (75.5) | 313 (62.1) | 436 (77.2) |
| β-blocker | 99 (18.9) | 132 (22.8) | 107 (21) | 132 (23) |
| α-blocker | 12 (2.3) | 34 (5.9) | 18 (3.6) | 30 (5.3) |
| Anti-aldosterone | 6 (1.2) | 13 (2.3) | 23 (4.6) | 31 (5.5) |
| Others | 1 (0.2) | 1 (0.2) | 2 (0.4) | 4 (0.7) |
| Statins | 140 (26.7) | 141 (24.4) | 188 (37.3) | 211 (37.4) |
| Antiplatelet | 80 (15.3) | 73 (12.6) | 87 (17.3) | 82 (14.5) |
| K supplement | 0 (0) | 0 (0) | 1 (0.2) | 2 (0.4) |
| Drugs for hyperuricaemia | 34 (6.5) | 36 (6.2) | 58 (11.5) | 51 (9.0) |
Data are number (%).
ARB, angiotensin receptor blocker.